UNION therapeutics A/S announces new paper on clinical potential of the emerging class of PDE4B/D inhibitors published in journal of Dermatology and Therapy
PDE4-inhibition is a well-established mechanism of action typically used for first line of treatment due to a well-documented safety and tolerability profile As the understanding of PDE4 inhibition has evolved, […]
UNION therapeutics A/S announces publication of results from the IASOS Phase 2b study of orismilast in psoriasis in Journal of the American Academy of Dermatology
In the Phase 2b study, orismilast significantly reduced Psoriasis Area and Severity Index (PASI) compared with placebo from baseline to week 16 39.5% to 49.0% of patients treated with orismilast […]
UNION therapeutics A/S completes patient enrollment for ADESOS Phase 2b study of orismilast in patients with atopic dermatitis
Topline results are expected in the first half of 2024 Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the developed world and a significant unmet […]
UNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in Boston
Hellerup, Denmark, October 25, 2023 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. […]
UNION therapeutics announces presentation of new data on orismilast at the EADV Congress 2023
Late-breaking presentation of data from the OSIRIS IIT PoC study of oral orismilast in hidradenitis suppurativa (HS) at the European Academy of Dermatology and Venerology Congress 2023 Additional e-posters on […]
UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa
Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast Study supports the dose-finding results from the recent IASOS Phase 2b […]
Announcement of topline results from the PROTECT-V platform study investigating niclosamide nasal spray to prevent COVID-19 infection in vaccinated but highly vulnerable patients
Hellerup, Denmark, June 16, 2023 – UNION therapeutics A/S, a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced topline results from the niclosamide arm […]
UNION therapeutics to present at 4th Annual Dermatology Drug Development Summit Europe
Hellerup, Denmark, May 10, 2023 – UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim […]
UNION therapeutics to participate at Kempen Life Science Conference
Hellerup, Denmark, April 21, 2023 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced participation at the Kempen […]
UNION therapeutics announces presentation of Phase 2b results with oral orismilast at the AAD Annual Meeting 2023
Late-breaking presentation of results from the Phase 2b IASOS study of oral orismilast in psoriasis to be presented at the American Academy of Dermatology (AAD) Annual Meeting 2023 Positive topline […]
